Clinical Trials on H5N1 Virus

Total 23353 results

National Institute of Allergy and Infectious Diseases...

Completed

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | Orthomyxovirdae

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety Study of Avian Flu Vaccine

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | Orthomyxoviridae | H5N1 Virus

United States
Biomedical Advanced Research and Development Authority
PPD

Completed

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

A/Vietnam/H5N1 Influenza Virus

United States
National Institute of Allergy and Infectious Diseases...
Emory University

Completed

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Influenza A Virus, H5N1 Subtype

United States
National Institute of Allergy and Infectious Diseases...

Completed

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Influenza A Virus, H5N1 Subtype

United States
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Pandemic H5N1 Influenza

United States, Australia, Thailand
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

Pandemic H5N1 Influenza

Poland, Turkey
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine

H5N1 Influenza

United States
Ology Bioservices
Baxter Innovations GmbH

Completed

H5N1 Vaccine Study in Japanese Adults

H5N1 Influenza

Japan
National Institute of Allergy and Infectious Diseases...

Completed

Experimental AD4-H5-VTN Vaccine in Healthy Volunteers

H5N1 Influenza

United States
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

United States, Australia, New Zealand, Thailand
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Pandemic H5N1 Influenza

United States, Thailand
Institute of Vaccines and Medical Biologicals,...
Department of Health and Human Services; Institut Pasteur; PATH; World Health Organization

Completed

Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1

Influenza A Subtype H5N1 Infection

Vietnam
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
IDRI
Defense Advanced Research Projects Agency; Medicago

Completed

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

Influenza A Subtype H5N1 Infection

United States
Medigen Biotechnology Corporation

Completed

A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine

Avian Influenza | Bird Flu | Influenza A(H5N1)

Taiwan
Ology Bioservices

Completed

Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine

United States
South East Asia Infectious Disease Clinical Research...
University of Oxford; Wellcome Trust

Completed

Host Genetic Susceptibility to Avian Influenza A/H5N1

Influenza A Virus/H5N1 Subtype

Vietnam
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant

Influenza

United States
Fraunhofer, Center for Molecular Biotechnology

Completed

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

Healthy

United States
Intercell USA, Inc.

Completed

Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine

Healthy

Austria, Belgium
Biomedical Advanced Research and Development Authority

Completed

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Influenza A Virus, H5N1 Subtype

United States
Public Health England

Completed

A Study to Validate a New Oral Fluid/Saliva Antibody Test for Novel H1N1v Influenza (Snuffles)

H1N1 Virus
UMN Pharma Inc.

Completed

Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

Virus Diseases | Influenza

Japan
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

Influenza

United States
GlaxoSmithKline

Completed

A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64

Influenza

Canada
GlaxoSmithKline
United States Department of Health and Human Services, Center for Disease...

Withdrawn

Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Influenza

United States
VaxInnate Corporation

Completed

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

A/H5N1in Adult - Aventis

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With AS03

Influenza

United States
Sanofi

Completed

Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine

Influenza | Orthomyxoviridae Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 (Clade 2) Vaccination of Adults and Elderly

Influenza

United States
VaxInnate Corporation

Completed

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Inactivated Influenza A/H5N1 Vaccine in the Elderly

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine

Influenza

United States
UMN Pharma Inc.

Completed

Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults

Influenza

Japan
National Institute of Allergy and Infectious Diseases...

Completed

Prospective Study of AI H5N1 in China

Influenza

China
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

Influenza

Poland
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response (HIPCVAX-010S)

Influenza A Subtype H5N1 Infection

United States
Rebecca Cox
Haukeland University Hospital; European Commission

Completed

Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults (PANFLUVAC)

Healthy | Influenza

Norway
Jiangsu Province Centers for Disease Control and...
Wuhan Institute of Biological Products Co., Ltd

Withdrawn

A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults

Healthy

China
Gamaleya Research Institute of Epidemiology and...

Completed

The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac

Influenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1

Russian Federation
National Institute of Allergy and Infectious Diseases...

Completed

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults

Influenza

Italy
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Priming and Boosting Strategies

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine

Influenza

United States

Clinical Trials on H5N1 Virus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations